LIXTE-logo-web-horz-black-190LIXTE-logo-web-horz-black-190LIXTE-logo-web-horz-black-190LIXTE-logo-web-horz-black-190
  • Our Approach
  • Science
  • Programs
  • Team
  • Investor Information
✕
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Articles
  • Podcast
  • Video
  • All
  • All
  • lixte-biotech
May 1, 2024
MedInvest Biotech and Pharma Conference Presentation
Published by lixte-biotech on May 1, 2024
Categories
  • Video

Video: MedInvest Biotech and Pharma Conference Presentation

Lixte’s CEO Bas van der Baan presented at MedInvest Biotech and Pharma Conference, April 3-4, […]
Do you like it?
Read more
March 20, 2024
Update on Progress with Proprietary LB-100 Compound
Published by lixte-biotech on March 20, 2024
Categories
  • Video

Video: Update on Progress with Proprietary LB-100 Compound

LIXTE Biotechnology Holdings Provides Update on Progress with Proprietary LB-100 Compound to Enhance Chemotherapy and […]
Do you like it?
Read more
December 21, 2023
Developing the drug LB-100 to inhibit PP2A
Published by lixte-biotech on December 21, 2023
Categories
  • Video

Video: Developing the drug LB-100 to inhibit PP2A

Researchers at the National Institute of Health as well as the Netherlands Cancer Institute and […]
Do you like it?
Read more

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing innovative cancer therapies and oncology treatments using PP2A inhibition with LB-100.

CONTACT

LIXTE Biotechnology Holdings, Inc.
680 E Colorado Blvd., Suite 180
Pasadena, CA 91101

General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
Fax: (631) 982-5050
Email: info@lixte.com

LIXTE Biotechnology Holdings, Inc.
is publicly traded as LIXT.

Privacy Policy | Terms of Use

  • Our Approach
  • Science
  • Programs
  • Team
  • Investor Information
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
© 2025 LIXTE Biotechnology Holdings, Inc. (LIXTE). All Rights Reserved. | Site by Third Eye Industries